Sumitomo Pharma Q1 FY27 net profit rises 51.7% to JPY 17 billion; revenue increases 19.9% to JPY 129.5 billion
Sumitomo Pharma keeps FY2026 forecasts unchanged
Poxel Publishes Its Turnover for the Second Quarter of 2026 and Announces the Postponement of the Publication of Its 2025 Financial Statements
Poxel expects 2026 TWYMEEG Japan royalties to rise to 12% on Sumitomo sales forecast
Sumitomo Pharma, Novo Nordisk’s Wegovy wins Japan approval for MASH indication
Japan Approves Pioneering Regenerative Medicine Products Using iPS Cells